Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON

Современная онкология

Antonina A. Teterich¹  Mikhail Yu. Fedyanin²  Alexey A. Tryakin²  Nikolai Iu. Sokolov³  Evgenii O. Mantsyrev⁴  Natalia V. Fadeeva⁴  Dmitrii Yu. Chobanu⁵  Elvira A. Bobrova⁶  Daniil L. Stroyakovskiy⁷  Stanislav M. Borzyanitsa⁸  Alexander V. Sultanbaev⁹  Denis Yu. Yukalchuk^1,10  Svetlana A. Orlova^1,11  Alina Z. Isyangulova^1,11  Fedor V. Moiseenko^1,12  Oleg V. Mironov^1,13  Yuliia A. Chernova^1,14  Aleksandra F. Saidullaeva^1,15  Kseniia G. Babina^1,16 

[1] Belgorod Oncological Dispensary;Blokhin National Medical Research Center of Oncology;Botkin Hospital;Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine;JSC "BIOCAD";Loginov Moscow Clinical Scientific Center;Moscow City Oncology Hospital №62;Rappoport Kuzbass Clinical Oncological Dispensary;Regional Oncological Clinical Dispensary;Regional Oncological Dispensary;Republican Clinical Oncological Dispensary;Saint Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care (Oncology);Tambov Regional Oncological Clinical Dispensary;Tomsk Regional Oncological Dispensary;Tver Regional Clinical Oncological Dispensary;Volgograd Regional Clinical Oncological Dispensary;

关键词: colorectal cancer;    antiangiogenic therapy;    bevacizumab;    avegra;   

DOI  :  10.26442/18151434.2021.4.201307

来源: DOAJ

【 授权许可】

Unknown